Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harold J Burstein

Showing results (41-50 of 251) with videos related to

Pageof 26
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|August 16, 2013
Lucky to be an oncologistHarold J Burstein
Oncology (Williston Park, N.Y.)|May 27, 2014
Neoadjuvant pertuzumab: the exception that proves the rule?Harold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2010
Addressing oncology pharmacy & policyHarold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|September 28, 2010
Avastin, ODAC, and the FDA: are we drafting the right players?Harold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|March 2, 2011
Take your medicineHarold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|April 6, 2011
Mind the gapHarold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|June 9, 2012
The top five in oncology: where do we go from here?Harold J Burstein
The New England Journal of Medicine|October 11, 2003
Beyond tamoxifen--extending endocrine treatment for early-stage breast cancerHarold J Burstein
Breast (Edinburgh, Scotland)|November 17, 2009
Late effects of adjuvant systemic therapies in women diagnosed with breast cancer at a young ageHarold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|November 26, 2009
Screening contretemps: the real issue in the mammogram guideline debateHarold J Burstein
Pageof 26

Showing results (41-50 of 251) with videos related to

Sort By:
Pageof 26
Journal of the National Comprehensive Cancer Network : JNCCN|August 16, 2013
Lucky to be an oncologistHarold J Burstein
Oncology (Williston Park, N.Y.)|May 27, 2014
Neoadjuvant pertuzumab: the exception that proves the rule?Harold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2010
Addressing oncology pharmacy & policyHarold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|September 28, 2010
Avastin, ODAC, and the FDA: are we drafting the right players?Harold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|March 2, 2011
Take your medicineHarold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|April 6, 2011
Mind the gapHarold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|June 9, 2012
The top five in oncology: where do we go from here?Harold J Burstein
The New England Journal of Medicine|October 11, 2003
Beyond tamoxifen--extending endocrine treatment for early-stage breast cancerHarold J Burstein
Breast (Edinburgh, Scotland)|November 17, 2009
Late effects of adjuvant systemic therapies in women diagnosed with breast cancer at a young ageHarold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|November 26, 2009
Screening contretemps: the real issue in the mammogram guideline debateHarold J Burstein
Pageof 26